BUSINESS
Mitsubishi Tanabe’s HIF-PH Inhibitor Shows Non-Inferiority to ESA in Japan PIII Study
Mitsubishi Tanabe Pharma’s oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat showed non-inferiority to an erythropoiesis stimulating agent (ESA) in mean hemoglobin levels in a Japan PIII study in non-dialysis-dependent chronic kidney disease (CKD) patients with anemia, the company said…
To read the full story
Related Article
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Leqembi Sustains Benefits in Early Alzheimer’s after 5 Years of Treatment
November 18, 2026
- Meiji Invests US$50 Million in Arcturus to Expand mRNA Collaboration
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





